ストックスクリーナーアプリを入手
20.18
1.13%
0.225
前日終値:
$19.96
開ける：
$19.95
24時間の取引高:
1.71M
Relative Volume:
0.16
時価総額：
$23.17B
収益：
$16.70B
当期純損益:
$-157.13M
株価収益率:
-139.59
EPS:
-0.1446
ネットキャッシュフロー:
$1.19B
1週間 パフォーマンス:
-0.07%
1か月 パフォーマンス:
+6.52%
6か月 パフォーマンス:
+44.80%
1年 パフォーマンス:
+16.81%
1日の値動き範囲:
$19.91
$20.20
1週間の範囲:
$19.81
$20.61
52週間の値動き範囲:
$12.46
$22.80
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
名前
Teva Pharmaceutical Industries Ltd Adr
セクター
電話
972 (3) 914-8213
住所
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
TEVA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.20 | 22.90B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
ZTS
Zoetis Inc
|
143.06 | 64.42B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.51 | 45.95B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
8.865 | 39.14B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
UTHR
United Therapeutics Corp
|
450.62 | 20.50B | 3.08B | 1.24B | 1.07B | 25.61 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-06 | 開始されました | Goldman | Buy |
| 2025-05-28 | 開始されました | Truist | Buy |
| 2025-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-07-10 | アップグレード | Argus | Hold → Buy |
| 2024-03-08 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-02-12 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | アップグレード | Jefferies | Hold → Buy |
| 2024-01-03 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-11-27 | アップグレード | UBS | Neutral → Buy |
| 2023-07-06 | アップグレード | UBS | Sell → Neutral |
| 2023-05-25 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-05-18 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-01-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-11-14 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-11-04 | ダウングレード | UBS | Neutral → Sell |
| 2022-10-21 | 再開されました | Jefferies | Buy |
| 2022-08-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-06-14 | 再開されました | UBS | Neutral |
| 2022-05-17 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-05-04 | ダウングレード | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-03-25 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | ダウングレード | Argus | Buy → Hold |
| 2021-10-28 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | ダウングレード | UBS | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | 開始されました | Oppenheimer | Perform |
| 2020-08-06 | アップグレード | Barclays | Underweight → Equal Weight |
| 2020-07-27 | 再開されました | Goldman | Neutral |
| 2020-06-01 | アップグレード | SunTrust | Hold → Buy |
| 2020-04-24 | 再開されました | Citigroup | Neutral |
| 2020-04-06 | アップグレード | UBS | Neutral → Buy |
| 2020-02-24 | ダウングレード | Edward Jones | Hold → Sell |
| 2019-11-12 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-10-17 | アップグレード | Gabelli & Co | Hold → Buy |
| 2019-08-07 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-07-19 | 開始されました | Wolfe Research | Peer Perform |
| 2019-07-15 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | 再開されました | Credit Suisse | Neutral |
| 2019-07-05 | アップグレード | Argus | Hold → Buy |
| 2019-06-11 | 開始されました | Barclays | Underweight |
| 2019-06-03 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-30 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | ダウングレード | UBS | Buy → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Hold |
| 2019-03-07 | 再開されました | UBS | Buy |
すべてを表示
Teva Pharmaceutical Industries Ltd Adr (TEVA) 最新ニュース
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight Quarters - The Motley Fool
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed - Ariva
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction - Ariva
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting - Sahm
Bayforest Capital Ltd Sells 3,875 Shares of Teva Pharmaceutical Industries Ltd. $TEVA - Defense World
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - Ariva
Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - inkl
Teva stock rises on launch of first generic weight loss GLP-1 drug - Investing.com Nigeria
Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN
Teva stock rises on launch of first generic weight loss GLP-1 drug By Investing.com - Investing.com South Africa
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss - Placera.se
TEVA Stock Price and Chart — TASE:TEVA - TradingView
TEVA Stock Price and Chart — NYSE:TEVA - TradingView
Earnings call transcript: Teva’s Q2 2025 earnings beat fails to lift revenue - Investing.com
Teva (TEVA) Is Up 5.7% After FDA Approves AJOVY for Pediatric Migraine Prevention - Sahm
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Navigating a Year of Volatility - investchronicle.com
Teva's AJOVY Receives FDA Approval for Pediatric Migraine Treatment - AInvest
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Ariva
TEVA’s Stock Market Puzzle: Piecing Together 2025’s Performance - investchronicle.com
Teva's Pivot to Growth Strategy Underway as Innovative Portfolio Impresses and Pipeline Looks Solid - Morningstar
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components - Ariva
Head-To-Head Contrast: Teva Pharmaceutical Industries (NYSE:TEVA) & Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Drops -2.31%, Turning Investors Away - Stocksregister
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?26.06.25News - Ariva
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Bought by Yousif Capital Management LLC - Defense World
Can Teva- Pharmaceutical Industries Ltd. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Stocks Generating Improved Relative Strength: Teva Pharmaceutical ADR - MSN
Teva: New Long-Term Targets and Sold Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar
Teva: New Long-Term Targets and Solid Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Yahoo Finance
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Restart of Student Loan Repayments Could Squeeze Consumer Spending and Slow Economic Growth - iHeart
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
Teva Earnings: Innovation Propels Sales and Generics Show Stability in Solid Start to the Year - Morningstar
Teva and Alvotech stocks jump on FDA approval of SELARSDI - Investing.com
Teva and Alvotech stocks jump on FDA approval of SELARSDI By Investing.com - Investing.com Canada
Teva Pharmaceutical Industries Ltd Adr (TEVA) 財務データ
収益
当期純利益
現金流量
EPS
0.44%
0.89%
大文字化:
|
ボリューム (24 時間):